Fortress Biotech, Inc. (FBIOP) Cash & Equivalents (2010 - 2026)

Fortress Biotech's Cash & Equivalents history runs 16 years deep, the most recent figure standing at $79.4 million for Q4 2025.

• In Q4 2025, Cash & Equivalents rose 38.63% year-over-year to $79.4 million; the TTM figure through Dec 2025 stood at $79.4 million (up 38.63% YoY), while the FY2025 annual figure was $79.4 million, up 38.63% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $79.4 million, down from $86.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $305.7 million in Q4 2021, with the low at $57.3 million in Q4 2024.
• The 5-year median for Cash & Equivalents is $88.8 million (2025), against an average of $151.9 million.
• The sharpest annual moves came in 2021 and 2023: Cash & Equivalents jumped 2500.44% in 2021, then tumbled 68.64% in 2023.
• Fortress Biotech's Cash & Equivalents stood at $305.7 million in 2021, then tumbled by 41.69% to $178.3 million in 2022, then plunged by 54.6% to $80.9 million in 2023, then declined by 29.24% to $57.3 million in 2024, then soared by 38.63% to $79.4 million in 2025.
• Business Quant data shows FBIOP's Cash & Equivalents at $79.4 million in Q4 2025, $86.2 million in Q3 2025, and $74.4 million in Q2 2025.